Mark Benson

Dr. Mark Benson


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Science Advances
Verified
Journal Article
Open access
DKDaniel H. Katz
Daniel H. Katz
JRJeremy M. Robbins
Jeremy M. Robbins
SDShuliang Deng
Shuliang Deng
UTUsman A. Tahir
Usman A. Tahir
ABAlexander G. Bick
Alexander G. Bick
RGRobert Edgardo Gerszten
Robert Edgardo Gerszten
High-throughput proteomic profiling using antibody or aptamer-based affinity reagents is used increasingly in human studies. However, direct analyses to address the relative strengths and weaknesses of these platforms are lacking. We assessed findings from the SomaScan1.3K ( N = 1301 reagents), the SomaScan5K platform ( N = 4979 reagents), and the Olink Explore ( N = 1472 reagents) profiling techniques in 568 adults from the Jackson Heart Study and 219 participants in the HERITAGE Family Study across four performance domains: precision, accuracy, analytic breadth, and phenotypic associations leveraging detailed clinical phenotyping and genetic data. Across these studies, we show evidence supporting more reliable protein target specificity and a higher number of phenotypic associations for the Olink platform, while the Soma platforms benefit from greater measurement precision and analytic breadth across the proteome.

6 March 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
JRJason D. Roh
Jason D. Roh
RHRyan Hobson
Ryan Hobson
VCVinita Chaudhari
Vinita Chaudhari
PQPablo Quintero
Pablo Quintero
AYAshish Yeri
Ashish Yeri
ARAnthony Rosenzweig
Anthony Rosenzweig
Activin type II receptor (ActRII) ligands have been implicated in muscle wasting in aging and disease. However, the role of these ligands and ActRII signaling in the heart remains unclear. Here, we investigated this catabolic pathway in human aging and heart failure (HF) using circulating follistatin-like 3 (FSTL3) as a potential indicator of systemic ActRII activity. FSTL3 is a downstream regulator of ActRII signaling, whose expression is up-regulated by the major ActRII ligands, activin A, circulating growth differentiation factor-8 (GDF8), and GDF11. In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins. In mice, increasing circulating activin A increased cardiac ActRII signaling and FSTL3 expression, as well as impaired cardiac function. Conversely, ActRII blockade with either clinical-stage inhibitors or genetic ablation reduced cardiac ActRII signaling while restoring or preserving cardiac function in multiple models of HF induced by aging, sarcomere mutation, or pressure overload. Using unbiased RNA sequencing, we show that activin A, GDF8, and GDF11 all induce a similar pathologic profile associated with up-regulation of the proteasome pathway in mammalian cardiomyocytes. The E3 ubiquitin ligase, Smurf1, was identified as a key downstream effector of activin-mediated ActRII signaling, which increased proteasome-dependent degradation of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), a critical determinant of cardiomyocyte function. Together, our findings suggest that increased activin/ActRII signaling links aging and HF pathobiology and that targeted inhibition of this catabolic pathway holds promise as a therapeutic strategy for multiple forms of HF.

18 March 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SXShuke Xiao
Shuke Xiao
VLVeronica L. Li
Veronica L. Li
XLXuchao Lyu
Xuchao Lyu
XCXudong Chen
Xudong Chen
WWWei Wei
Wei Wei
JLJonathan Z. Long
Jonathan Z. Long

8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
DNDebby Ngo
Debby Ngo
MBMark Benson
Mark Benson
JLJonathan Z. Long
Jonathan Z. Long
ZCZsu-Zsu Chen
Zsu-Zsu Chen
RWRuiqi Wang
Ruiqi Wang
RGRobert Edgardo Gerszten
Robert Edgardo Gerszten
Recent advances in proteomic technologies have made high-throughput profiling of low-abundance proteins in large epidemiological cohorts increasingly feasible. We investigated whether aptamer-based proteomic profiling could identify biomarkers associated with future development of type 2 diabetes (T2DM) beyond known risk factors. We identified dozens of markers with highly significant associations with future T2DM across 2 large longitudinal cohorts ( n = 2839) followed for up to 16 years. We leveraged proteomic, metabolomic, genetic, and clinical data from humans to nominate 1 specific candidate to test for potential causal relationships in model systems. Our studies identified functional effects of aminoacylase 1 (ACY1), a top protein association with future T2DM risk, on amino acid metabolism and insulin homeostasis in vitro and in vivo. Furthermore, a loss-of-function variant associated with circulating levels of the biomarker WAP, Kazal, immunoglobulin, Kunitz, and NTR domain–containing protein 2 (WFIKKN2) was, in turn, associated with fasting glucose, hemoglobin A1c, and HOMA-IR measurements in humans. In addition to identifying potentially novel disease markers and pathways in T2DM, we provide publicly available data to be leveraged for insights about gene function and disease pathogenesis in the context of human metabolism.

22 October 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
JFJocelyn R. Farmer
Jocelyn R. Farmer
HAHugues Allard-Chamard
Hugues Allard-Chamard
NSNa Sun
Na Sun
MAMaimuna Ahmad
Maimuna Ahmad
ABAlice Bertocchi
Alice Bertocchi
SPShiv Pillai
Shiv Pillai
Transitional B cells must actively undergo selection for self-tolerance before maturing into their resting follicular B cell successors. We found that metabolic quiescence was acquired at the follicular B cell stage in both humans and mice. In follicular B cells, the expression of genes involved in ribosome biogenesis, aerobic respiration, and mammalian target of rapamycin complex 1 (mTORC1) signaling was reduced when compared to that in transitional B cells. Functional metabolism studies, profiling of whole-cell metabolites, and analysis of cell surface proteins in human B cells suggested that this transition was also associated with increased extracellular adenosine salvage. Follicular B cells increased the abundance of the cell surface ectonucleotidase CD73, which coincided with adenosine 5′-monophosphate–activated protein kinase (AMPK) activation. Differentiation to the follicular B cell stage in vitro correlated with surface acquisition of CD73 on human transitional B cells and was augmented with the AMPK agonist, AICAR. Last, individuals with gain-of-function PIK3CD (PI3Kδ) mutations and increased pS6 activation exhibited a near absence of circulating follicular B cells. Together, our data suggest that mTORC1 attenuation may be necessary for human follicular B cell development. These data identify a distinct metabolic switch during human B cell development at the transitional to follicular stages, which is characterized by an induction of extracellular adenosine salvage, AMPK activation, and the acquisition of metabolic quiescence.

14 August 2023 in Cell Metabolism
Verified
Journal Article
Closed access
MBMark Benson
Mark Benson
AEAaron S. Eisman
Aaron S. Eisman
UTUsman A. Tahir
Usman A. Tahir
DKDaniel H. Katz
Daniel H. Katz
SDShuliang Deng
Shuliang Deng
RGRobert Edgardo Gerszten
Robert Edgardo Gerszten